XL t(6;9) DEK/NUP214

Translocation/Dual Fusion Probe

Order Number
Package Size
100 µl (10 Tests)


XL t(6;9) DEK/NUP214

The XL t(6;9) DEK/NUP214 is designed as a dual fusion probe. The green labeled probe spans the breakpoint at 6p22 (DEK), and the orange labeled probe spans the breakpoint at 9q34 (NUP214).

Need Help?

Clinical Details

Several recurrent balanced translocations and inversions, and their variants, are
recognized in the WHO category AML with recurrent genetic abnormalities. Three new
cytogenetically defined entities were recently incorporated: AML with t(6;9)(p23;q34) DEK/NUP214; AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) RPN1/EVI1 and AML (megakaryoblastic) with t(1;22)(p13;q13) RBM15/MKL1, a rare leukemia most commonly
occurring in infants.

The t(6;9)(p23;q34) DEK/NUP214 fusion occurs with an incidence of 1–5% in adult patients with AML. This translocation tends to occur in younger adults and is associated with an unfavorable prognosis at diagnosis. Although the t(6;9) is usually the sole cytogenetic aberration at diagnosis, additional karyotypic abnormalities are frequently identified during disease progression.

Clinical Applications

  • Acute Myelogenous Leukemia (AML)
Need Help?


XL t(6;9) DEK/NUP214

XL t(6;9) DEK/NUP214 hybridized to lymphocytes. One normal metaphase is shown.

Need Help?

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange fusion signals (2GO).

Need Help?


  • Shearer et al (2005) Leukemia 19: 126-131
  • Doehner et al (2010) Blood 115: 453-474
  • Sandahl et al (2014) Haematologica 99: 865-872